What question did this study set out to answer?

To assess the efficacy and safety of ustekinumab biosimilar in Crohn’s Disease patients, both after switching from originator ustekinumab and in treatment-naïve individuals.

January 23, 2026Journal of Crohn s and Colitis

P0836Short and medium-term outcomes of ustekinumab biosimilar in patients with Crohn’s Disease

View Full Paper

Ask AI

Bookmark

To assess the efficacy and safety of ustekinumab biosimilar in Crohn’s Disease patients, both after switching from originator ustekinumab and in treatment-naïve individuals.
Conducted a bicentric retrospective analysis.
Included Crohn’s Disease patients who switched from originator ustekinumab or were ustekinumab-naïve.
Collected clinical, biochemical, and safety data at baseline, 3–4 months, and 6 months.
In the switch cohort, 94.5% persisted on the biosimilar at 6 months.
70% of the UST-initiation cohort achieved steroid-free clinical remission at 3-4 months.
No significant differences observed in fecal calprotectin levels pre- and post-treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Retrospective study evaluates efficacy and safety of ustekinumab biosimilar in Crohn’s Disease, suggesting positive outcomes for patients.

Cite This Study

Fuentes-Valenzuela et al. (2026) studied this question.

synapsesocial.com/papers/69730f18c8125b09b0d1ee2c https://doi.org/10.1093/ecco-jcc/jjaf231.1017

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study evaluates efficacy and safety of ustekinumab biosimilar in Crohn’s Disease, suggesting positive outcomes for patients.

P0836Short and medium-term outcomes of ustekinumab biosimilar in patients with Crohn’s Disease

Key Points

Discussion

Implication

Cite This Study

P0836Short and medium-term outcomes of ustekinumab biosimilar in patients with Crohn’s Disease

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider